4U Solutions and Headsafe US strike regional concussion device partnership

4U Solutions and Headsafe US have formed a distribution partnership to expand access to Headsafe’s Nurochek portable EEG system in Pennsylvania, Ohio and West Virginia. The deal aims to speed objective concussion assessment in healthcare settings where fast diagnosis can affect care decisions.

Why it matters: - The partnership gives Headsafe US a regional distribution partner with direct reach into hospitals and community providers across three states. - Nurochek is an FDA-cleared tool that adds objective brain function data to concussion evaluations, which can support faster clinical decisions. - The deal expands access to a device intended for use where timely assessment of mild traumatic brain injury matters most.

What happened: - 4U Solutions and Headsafe US announced a new distribution partnership on June 9, 2026. - 4U Solutions will support regional distribution and commercial activity for Nurochek in Pennsylvania, Ohio and West Virginia. - Headsafe US is commercializing objective concussion assessment solutions in the United States.

The details: - 4U Solutions is an independent distributor of technology-based medical devices based in Latrobe, Pennsylvania. - The company operates through offices in Pennsylvania, Ohio and West Virginia and offers same-day service to major medical and community centers across the region. - Nurochek is an FDA-cleared portable EEG system used as an aid to the diagnosis of concussion, also known as mild traumatic brain injury. - The system uses visual evoked potentials and EEG sensors in the headset to capture and analyze brain-response data. - Nurochek delivers results in about two minutes and does not require a baseline test. - Headsafe said the partnership strengthens its U.S. commercialization effort and broadens access to objective concussion assessment across the three-state region. - The company also said the agreement should support its broader U.S. commercialization strategy by pairing Nurochek with an experienced regional distributor.

Between the lines: - The partnership appears designed to solve two market problems at once: limited local distribution and the need for more objective concussion assessment tools. - Headsafe is leaning on a regional partner with established healthcare relationships to drive adoption in settings such as hospitals, urgent care, neurology clinics and sports medicine practices. - The move also signals that Headsafe is prioritizing real-world implementation, training and workflow integration rather than a product-only rollout.

What’s next: - 4U Solutions is expected to help broaden sales and support for Nurochek across key Mid-Atlantic healthcare markets. - Headsafe will continue its U.S. commercialization push with a focus on practical adoption in clinical settings. - Nurochek remains cleared for sale in the United States only and is not approved or cleared for sale in Australia, the European Union or other markets at this time. - The device is cleared as an aid in diagnosing concussion when used with a standard neurological assessment, for patients ages 12 to 44 within 120 hours of a potential head injury, with exclusion criteria that include seizure history, epilepsy, existing structural brain injuries and legal blindness.